// App-Quantinova.ai

2556 : A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.

Researchers

Presenter

  • Kwang-Yu Chang

Principal Investigators

  • Nai-Jung Chiang

  • Chia-Jui Yen

  • Shang-Yin Wu

  • Shang-Hung Chen

  • Amanda Johnston

  • John S. Bomalaski

  • Bor-Wen Wu

  • Li-Tzong Chen

Medical Centers

  • National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

  • Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan

  • Polaris Pharmaceuticals Inc, San Diego, CA

Locations

  • United States

  • Taiwan

Companies

  • Polaris Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Pegargiminase

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03254732

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved